Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)

Introduction: EGFR-mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed in EGFR-mutant NSCLC after progression with EGFR tyrosine kinase inhibitors (TKIs). M...

Full description

Saved in:
Bibliographic Details
Main Authors: Chee Khoon Lee, PhD, Bin-Chi Liao, MD, Shalini Subramaniam, MMed (Clin Epi), Chao-Hua Chiu, MD, Antony J. Mersiades, MMed (Clin Epi), Chao-Chi Ho, MD, PhD, Chris Brown, MBiostats, Chun-Liang Lai, MD, PhD, Brett G.M. Hughes, M.B.B.S. (Hons), Tsung-Ying Yang, MD, PhD, Ken O’Byrne, MD, Yung-Hung Luo, MD, PhD, Sonia Yip, PhD, Ching-Liang Ho, MD, Victoria Bray, PhD, Wu-Chou Su, MD, PhD, Melissa Moore, PhD, Wei-Lien Feng, MS, Ya-Ying Bai, MS, Kate Ford, MHSc, Michelle M. Cummins, PhD, Martin R. Stockler, MSc (Clin Epi), Benjamin J. Solomon, PhD, Thomas John, PhD, James Chih-Hsin Yang, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JTO Clinical and Research Reports
Subjects:
Non-small cell lung cancer
EGFR mutation
Checkpoint inhibitors
Chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001413
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items